DDR2 and neoplasm: Dasatinib, nilotinib, a DDR1 blocking antibody, the selective DDR1 inhibitors 7rh and DDR1-IN-1 and the selective allosteric DDR2 inhibitor WRG-28 were shown to efficiently prevent DDR-mediated tumor progression in preclinical models (Table 1).